[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Invivyd Inc (IVVD)

Invivyd Inc (IVVD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 281,465
  • Shares Outstanding, K 294,759
  • Annual Sales, $ 53,430 K
  • Annual Income, $ -52,490 K
  • EBIT $ -113 M
  • EBITDA $ -110 M
  • 60-Month Beta 0.71
  • Price/Sales 5.32
  • Price/Cash Flow N/A
  • Price/Book 1.47
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.33
  • Most Recent Earnings $-0.14 on 08/13/26
  • Next Earnings Date 11/05/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 273.45% (+55.63%)
  • Historical Volatility 100.47%
  • IV Percentile 90%
  • IV Rank 34.28%
  • IV High 671.77% on 07/24/26
  • IV Low 65.69% on 05/19/26
  • Expected Move (DTE 17) 0.3315 (34.72%)
  • Put/Call Vol Ratio 0.14
  • Today's Volume 2,285
  • Volume Avg (30-Day) 1,557
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 37,880
  • Open Int (30-Day) 30,783
  • Expected Range 0.6234 to 1.2864

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.11
  • Number of Estimates 1
  • High Estimate $-0.11
  • Low Estimate $-0.11
  • Prior Year $-0.06
  • Growth Rate Est. (year over year) -83.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5447 +75.31%
on 08/03/26
1.0500 -9.06%
on 08/20/26
+0.4199 (+78.49%)
since 07/31/26
3-Month
0.5277 +80.96%
on 07/31/26
1.2500 -23.61%
on 06/01/26
-0.1851 (-16.24%)
since 05/29/26
52-Week
0.5277 +80.96%
on 07/31/26
3.0699 -68.89%
on 11/17/25
-0.0351 (-3.55%)
since 08/28/25

Most Recent Stories

More News
Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY

Mr. Elia has served as Chairman of Invivyd’s Board of Directors since June of 2022; has architected Invivyd’s scientific and corporate strategy Ajay Royan, Founder of Mithril Capital and a founding,...

IVVD : 0.9549 (-1.00%)
Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Achieved Q2 2026 PEMGARDA® (pemivibart) net product revenue of $14.3 million, representing 21% growth versus Q2 2025 net product revenue of $11.8...

IVVD : 0.9549 (-1.00%)
Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Achieved Q2 2026 PEMGARDA ® (pemivibart) net product revenue of $14.3 million, representing 21% growth versus Q2 2025 net product revenue of $11.8 million Completed rapid enrollment in VYD2311 DECLARATION...

IVVD : 0.9549 (-1.00%)
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 

NEW HAVEN, Conn., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on August 1, 2026, Invivyd granted ten newly hired non-executive employees options to purchase an...

IVVD : 0.9549 (-1.00%)
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW HAVEN, Conn., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on August 1, 2026, Invivyd granted ten newly hired non-executive employees options to purchase an...

IVVD : 0.9549 (-1.00%)
Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA

U.S. Department of Health and Human Services (HHS) announced advanced Notice of Termination of the COVID-19 EUA declaration, effective June 29, 2027  Consequently, Invivyd received from the U.S. Food...

IVVD : 0.9549 (-1.00%)
Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA

U.S. Department of Health and Human Services (HHS) announced advanced Notice of Termination of the COVID-19 EUA declaration, effective June 29,...

IVVD : 0.9549 (-1.00%)
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW HAVEN, Conn., July 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on July 1, 2026, Invivyd granted 14 newly hired non-executive employees options to purchase an aggregate...

IVVD : 0.9549 (-1.00%)
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW HAVEN, Conn., July 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on July 1, 2026, Invivyd granted 14 newly hired...

IVVD : 0.9549 (-1.00%)
NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer

ROCKVILLE, Md., June 29, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative medicines...

IVVD : 0.9549 (-1.00%)
NBP : 1.8200 (-1.09%)

Business Summary

INVIVYD INC. is a biopharmaceutical company. It involved in developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. INVIVYD INC., formerly known as Adagio Therapeutics, is based in WALTHAM, Mass.

See More

Key Turning Points

3rd Resistance Point 1.0635
2nd Resistance Point 1.0368
1st Resistance Point 0.9958
Last Price 0.9549
1st Support Level 0.9281
2nd Support Level 0.9014
3rd Support Level 0.8604

See More

52-Week High 3.0699
Fibonacci 61.8% 2.0988
Fibonacci 50% 1.7988
Fibonacci 38.2% 1.4988
Last Price 0.9549
52-Week Low 0.5277

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.